1. Scrip

The Next Wave Of US Humira Biosimilars

Generics Bulletin Explains The Coming Adalimumab Competitors

 
• By Dave Wallace

Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.

Black running track with white markings for positions 1 to 8
Eight further FDA-approved Humira biosimilars are set to launch • Source: Shutterstock

Anyone with even a passing interest in the global off-patent industry will likely be aware of the significance of 2023 for the US biosimilars market.

FDA-approved adalimumab biosimilars

Amgen’s Amjevita (adalimumab-atto)

Biocon’s Hulio (adalimumab-fkjp)

Boehringer Ingelheim’s Cyltezo (adalimumab-adbm)

Celltrion’s Yuflyma (adalimumab-aaty)

Coherus’s Yusimry (adalimumab-aqvh)

Fresenius Kabi’s Idacio (adalimumab-aacf)

Humira – for a long time the world’s top-selling drug, and still one of the biggest brands in the business – finally faced US biosimilar competition this year, with Amgen at the end of January launching the first of many

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.